2017
DOI: 10.1111/1440-1681.12743
|View full text |Cite
|
Sign up to set email alerts
|

Gastric cancer management: Kinases as a target therapy

Abstract: Summary The molecular diagnostics revolution has reshaped the practice of oncology by facilitating the identification of genetic, epigenetic and proteomic modifications correlated with cancer, thus delineating ‘oncomaps’ for various cancer types. These advances have enhanced our understanding of gastric cancer, one of the most fatal diseases worldwide, and culminated in the approval of novel molecular therapies such as trastuzumab. Gastric tumours display recurrent aberrations in key kinase oncogenes such as H… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
24
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 31 publications
(24 citation statements)
references
References 90 publications
0
24
0
Order By: Relevance
“…The PI3K/AKT pathway is an important therapeutic target because its components, including PIK3CA, are frequently activated in cancer cells; indeed, several PI3K pathway inhibitors are currently in clinical trials [ 26 , 27 ]. Therefore, identifying patients who might benefit from targeted therapy is of great importance [ 28 , 29 ]. An increasing number of studies are focused on PIK3CA dysregulation and its potential impact in GC, one example being the MAGIC trial [ 30 ], highlighting the urgent need to elucidate more precisely the contribution of PIK3CA alterations to GC.…”
Section: Discussionmentioning
confidence: 99%
“…The PI3K/AKT pathway is an important therapeutic target because its components, including PIK3CA, are frequently activated in cancer cells; indeed, several PI3K pathway inhibitors are currently in clinical trials [ 26 , 27 ]. Therefore, identifying patients who might benefit from targeted therapy is of great importance [ 28 , 29 ]. An increasing number of studies are focused on PIK3CA dysregulation and its potential impact in GC, one example being the MAGIC trial [ 30 ], highlighting the urgent need to elucidate more precisely the contribution of PIK3CA alterations to GC.…”
Section: Discussionmentioning
confidence: 99%
“…The PTEN/PI3K/AKT axis is a crucial signaling pathway in various of tumor biological processes, [24][25][26][27] and molecules targeting PI3K pathway is widely used in GC therapies. 28,29 PIK3CA and PTEN mutations are common events in genetic mutations in cancer progression. [30][31][32] Previous study indicates that PIK3CA mutations are closely associated with survival time of patients with glioblastoma.…”
Section: Discussionmentioning
confidence: 99%
“…The efficacy of kinase inhibitors for many different types of cancers has prompted the investigation of these compounds also in GC [6,21,22]. However, so far most clinical trials (clinicaltrial.org NCT00215995, NCT00595985, NCT00725712) with for instance the dual MET/VEGFR2 inhibitor GSK1363089, the multi-target kinase inhibitor sunitinib and the Epidermal Growth Factor Receptor EGFR1 and EGFR2 inhibitor lapatinib, respectively, failed to show beneficial effects [23][24][25].…”
Section: Introductionmentioning
confidence: 99%